Cell therapy: types, regulation, and clinical benefits

AEH El-Kadiry, M Rafei, R Shammaa - Frontiers in Medicine, 2021 - frontiersin.org
Cell therapy practices date back to the 19th century and continue to expand on
investigational and investment grounds. Cell therapy includes stem cell-and non–stem cell …

Research progress of single-cell transcriptome sequencing in autoimmune diseases and autoinflammatory disease: A review

L Zeng, K Yang, T Zhang, X Zhu, W Hao, H Chen… - Journal of …, 2022 - Elsevier
Autoimmunity refers to the phenomenon that the body's immune system produces antibodies
or sensitized lymphocytes to its own tissues to cause an immune response. Immune …

Delivery of stem cell secretome for therapeutic applications

F Li, J Zhang, K Yi, H Wang, H Wei… - ACS Applied Bio …, 2022 - ACS Publications
Intensive studies on stem cell therapy reveal that benefits of stem cells attribute to the
paracrine effects. Hence, direct delivery of stem cell secretome to the injured site shows the …

Hematopoietic cell transplantation for systemic sclerosis—a review

D Levin, MS Osman, C Durand, H Kim, I Hemmati… - Cells, 2022 - mdpi.com
Systemic sclerosis (SSc) is an autoimmune, multi-organ, connective tissue disease
associated with significant morbidity and mortality. Conventional immunosuppressive …

Efficacy and safety of stem cell therapy for Crohn's disease: a meta-analysis of randomized controlled trials

Y Qiu, C Li, S Sheng - Stem Cell Research & Therapy, 2024 - Springer
Purpose Small-scale clinical trials have provided evidence suggesting the effectiveness of
stem-cell therapy (SCT) for patients diagnosed with Crohn's disease (CD). The objective of …

Steccherins A–D, chamigrane-type sesquiterpenes from the fungus Steccherinum ochraceum with selective inhibition on B lymphocyte proliferation

SS Huang, HX Yang, J He, BC Yan, T Feng, JK Liu - Phytochemistry, 2023 - Elsevier
Four previously undescribed chamigrane sesquiterpenes, namely steccherins A− D, have
been isolated from the fungus Steccherinum ochraceum. Their structures were elucidated by …

Advances in nanotechnology versus stem cell therapy for the theranostics of multiple sclerosis disease

AR Damavandi, O Mirmosayyeb, N Ebrahimi… - Applied …, 2023 - Springer
Multiple sclerosis (MS) is an autoimmune disease afflicting over 2.8 million people
worldwide. Symptoms of this disorder include discrepancies in speech, hearing impairment …

Research progress on the application of single-cell sequencing in autoimmune diseases

X Yang, X Hou, J Zhang, Z Liu, G Wang - Genes & Immunity, 2023 - nature.com
Autoimmune diseases (AIDs) are caused by immune tolerance deficiency or abnormal
immune regulation, leading to damage to host organs. The complicated pathogenesis and …

Day-1 CD34+ cells and platelet count predict the number of apheresis in poor-mobilizer patients rescued by plerixafor

CG Valentini, C Pellegrino, R Putzulu… - Journal of Clinical …, 2023 - mdpi.com
Plerixafor is widely used as up-front treatment with G-CSF to enhance peripheral blood
hematopoietic stem cell output in patients failing previous mobilizations. Less frequently …

Microvascular remodeling after autologous stem cell transplant in an overlap of systemic sclerosis and systemic lupus erythematosus: A case report

S Mumtaz, LM Balistreri, A Abril… - … Open Medical Case …, 2024 - journals.sagepub.com
Microvascular remodeling and capillary repopulation can occur after autologous
hematopoietic stem cell transplant (HSCT) in patients with systemic sclerosis and systemic …